Under the amendment to the initial agreement, Janssen will commit approximately $604 million and BARDA will commit approximately $454 million to support the ongoing phase III Ensemble clinical trial evaluating the investigational COVID-19 vaccine candidate as a single-dose in up to 60,000 volunteers worldwide.

If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...

J&J pauses COVID-19 vaccine trials
Johnson & Johnson on October 12 temporarily paused further dosing in all of its COVID-19 vaccine clinical trials, including the phase III Ensemble...

J&J to supply EU with 200M COVID-19 vaccine doses
Johnson & Johnson has received approval from the European Commission to supply 200 million doses of Janssen Pharmaceutical's COVID-19 vaccine...

National Institutes of Health launches 4th phase III COVID-19 vaccine study
A phase III clinical trial evaluating the investigational Janssen COVID-19 vaccine Ad26.COV2.S for the prevention of symptomatic COVID-19 in a single-dose...

J&J to provide U.S. with 100M doses of COVID-19 vaccine
Johnson & Johnson will manufacture and deliver 100 million doses of its SARS-CoV-2 investigational vaccine to the U.S. government once it receives...